Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
2LHERP
- Development stage
- Phase 4
- Lead developer
- Labo'Life
- Modality
- RNA Therapeutics → Nucleic Acid Therapeutics, Peptides
- Administration
- Oral, Sublingual
01
Overview
2LHERP is a micro-immunotherapy medicinal product developed by Labo'Life, designed as an immune regulator for the treatment and prevention of recurrent herpes simplex virus (HSV) infections, including genital and orofacial herpes. The drug is formulated based on the principles of micro-immunotherapy, which utilizes low doses (micro-doses) of immune-related substances to modulate the host's immune response. Specifically, 2LHERP contains a combination of cytokines, including Interleukin 1, Interleukin 2, and Interferon alpha, along with specific nucleic acids (SNA-HERP) that target the viral replication cycle. The treatment aims to reduce the frequency and severity of herpetic recurrences by enhancing the immune system's ability to maintain the virus in a latent state. It has been available for over 20 years and holds marketing authorization in Belgium. The drug is typically administered sublingually in a sequential manner using globules contained within capsules.
- Brand names
- 2LHERP
- Other names
- 2LHERP
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)IL-2R (Interleukin-2/interleukin-15 receptor complex)IL-1R (Interleukin-1 receptor type 1 (IL-1R1))HSV-1 (Herpes simplex virus type 1)
Beyond the preview
Go deeper on 2LHERP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 2LHERP.